Immutep Ltd. (IMMP) announced encouraging outcomes from the INSIGHT-003 Phase I trial on Thursday. This trial assessed the efficacy of adding Eftilagimod alpha (efti) to a regimen of Keytruda and chemotherapy for first-line treatment in patients with metastatic non-squamous non-small cell lung cancer.
The trial findings demonstrated a Median Overall Survival of 32.9 months, with a median Progression-Free Survival of 12.7 months. Furthermore, the 24-month Overall Survival rate stood at an impressive 81 percent.
Additionally, data from all evaluable patients to date indicated a notable enhancement in the Overall Response Rate when compared to historical controls.
As of now, shares of Immutep are trading at $2.09, an increase of 11.76 percent on the Nasdaq.
